Outcomes of Ahmed Glaucoma Valve Implantation with Subsequent Trans-Scleral Diode Cyclophotocoagulation as the Main Intervention if IOP Remained Medically Uncontrolled.
Document Type
Article
Publication Date
12-17-2024
Publication Title
Clinical Ophthalmology
Abstract
PURPOSE: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation with subsequent trans-scleral diode cyclophotocoagulation (CPC) as the main intervention if IOP remained medically uncontrolled.
PATIENTS AND METHODS: Charts of 108 consecutive eyes (90 patients) that underwent AGV implantation from 2003 to 2018 at a single clinical practice were retrospectively reviewed. The procedure was considered a failure if any of the following occurred: additional incisional glaucoma surgery, IOP >21 mmHg or < 20% reduction from baseline on 2 consecutive study visits after 3 months, IOP ≤ 5 mmHg on 2 consecutive study visits after 3 months, loss of light perception, or AGV removal.
RESULTS: The mean follow-up time was 5.4 ± 3.1 years. Diode CPC was performed in 32%. The mean IOP was 24.8 ± 8.2 mmHg before intervention, and 12.5 ± 5.6 mmHg at last follow-up (p
CONCLUSION: The treatment approach of AGV implantation with subsequent trans-scleral diode CPC, as needed, was successful in over 2/3rd of subjects. This study adds to the literature supporting the use of CPC when IOP is medically uncontrolled after AGV.
Volume
18
First Page
3825
Last Page
3836
Recommended Citation
Radhakrishnan S, Kots-Gotlib N, Pickering TD, McCurdy J, Siu J, Pham D, et al. Outcomes of Ahmed glaucoma valve implantation with subsequent trans-scleral diode cyclophotocoagulation as the main intervention if IOP remained medically uncontrolled. Clin Ophthalmol. 2024 Dec 17;18:3825-3836. doi: 10.2147/OPTH.S498973. PMID: 39712369.
DOI
10.2147/OPTH.S498973
ISSN
1177-5467
PubMed ID
39712369
